The top 8 children's pharmaceutical companies have made great achievements in half a year, and the most profitable one is it!

Wonderful content since 2015, the favorable policies of children's medicine have been continuous In addition to encouraging research and development, giving priority to evaluation, strengthening hospital equipment, bidding and purchasing, the children's medicine market has also become a hot industry under the policy dividend of full liberalization of the second child Now let's take a look at the wonderful performance of eight A-share listed children's drug companies in the first half of this year Table 1: performance of 8 A-share listed children's drug manufacturers in the first half of 2017 None = "shifumousedownstyle ('shifu bus_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border style: none none none Solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, Jichuan pharmaceutical industry adhered to the strategy of large varieties, actively developed market resources, and better completed various economic indicators The operating revenue was 2.81 billion yuan, an increase of 19.39% over the same period of last year, and the net profit attributable to shareholders of listed companies was 582 million yuan, an increase of 32.10% over the same period of last year Figure 1: performance of Jichuan pharmaceutical industry the main products of Jichuan pharmaceutical industry are Pudilan Xiaoyan oral liquid, rabeprazole sodium enteric coated capsule and xiaoerdaiqiaoqingre granules, etc In the first half of 2017, the total sales revenue of the three accounted for 77.28% of the current main business revenue In the first half of the year, the company's performance rose steadily, mainly due to the steady growth of sales revenue of core products such as Pudilan Xiaoyan oral liquid, rabeprazole sodium enteric coated capsule and xiaoerdaiqiaoqingre granules Xiaoer douqiaoqingre granule is the exclusive variety of Jichuan pharmaceutical industry, which belongs to class B medicine of medical insurance, and is mainly used to treat children's wind heat and cold According to the data of mienei.com, in 2013-2016, in the top 20 pattern of pediatric cold medicine brands in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (hereinafter referred to as "China's public medical institutions"), Jichuan pharmaceutical ranked first in terms of paediatric black bean qiaoqingre granules, with a market share of 32.81% higher than that in 2015   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, the performance of sunflower pharmaceutical industry grew faster than that of the previous year The operating income was 1 billion 957 million yuan, an increase of 27.46% over the same period of the previous year; the net profit attributable to the shareholders of the listed company was 192 million yuan, an increase of 15.30% over the same period of the previous year Figure 2: performance of sunflower pharmaceutical industry: the main products of sunflower pharmaceutical industry, such as liver protecting tablet, Xiaoer Feire Kechuan oral liquid, Xiaoer chaigui antipyretic granules, Weikangling capsule, Kangfu Xiaoyan suppository, are the leading varieties in their respective subdivisions, and their sales revenue has steadily increased Children's Paracetamol huangnamin granules, children's expectorant cough granules, children's Qingfei expectorant granules, mesalazine and other varieties maintain a good development trend   According to the data of minenet, from 2013 to 2016, in the top 20 pattern of pediatric cold medicine brand of proprietary Chinese medicine in China's public medical institutions, sunflower pediatric chaigui antipyretic granules ranked second, accounting for 8.89% of the total in 2016; in the top 20 pattern of pediatric antitussive and expectorant medicine brand of proprietary Chinese medicine in China's public medical institutions, sunflower pediatric Feire Kechuan oral liquid ranked sixth, accounting for 2016 Its market share is 5.34% In the first half of 2017, sunflower pharmaceutical industry further focused on the "variety upgrading" strategy, focusing on expanding the children's medicine category, vigorously creating "gold big single", and improving the company's industrial status through the creation of gold big single   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> in the first half of 2017, Jianmin group deepened its core business, strengthened the construction of R & D, manufacturing, management, marketing, culture and other basic systems, cultivated carefully, kept the company's income and profits growing steadily, and gradually improved its asset quality and operation level The operating revenue was 1.475 billion yuan, an increase of 26.97% year on year; the net profit attributable to the shareholders of the listed company was 48 million yuan, an increase of 14.71% year on year Figure 3: performance of Jianmin group Jianmin group focuses on Pediatrics, gynecology, elderly and other treatment fields The main products of Pediatrics include Longmu Zhuanggu granules, Xiaoer baotaikang granules, Xiaoer Xuanfei Zhike granules, etc As the exclusive product of Jianmin group, Longmu Zhuanggu Granule is a best-selling product in the retail market In 2016, it ranked first in the top 20 pediatric supplementary nutrition drugs in Chinese urban retail pharmacies with a market share of 92.71% Paediatric baotaikang granules is another best-selling paediatric drug of the company In 2016, it ranked ninth in the top 20 brand pattern of Chinese patent medicine paediatric cough and expectorant drugs in public medical institutions in China Xiao'er Xuanfei Zhike granule is a national second-class traditional Chinese medicine protection variety Jianmin group said that it will promote the re development of classical prescriptions, explore the traditional Chinese medicine research and development mode of disease integration, and speed up the research and development of new drugs In the first half of this year, phase III clinical research of Xiaoer Xuanfei Zhike syrup and phase III clinical research of Niuhuang Xiaoer antipyretic plaster progressed smoothly   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, Guizhou bailing's profitability improved significantly, achieving an operating income of 1.229 billion yuan, an increase of 20.07% over the same period last year; net profit attributable to shareholders of listed companies was 239 million yuan, an increase of 10.58% over the same period last year Figure 4: performance of Guizhou bailing Guizhou bailing products occupy a certain market share in cardiovascular and cerebrovascular, cough, cold and children's drug markets Paediatric chaigui antipyretic granules is one of the company's main profitable products According to the data of mienei.com, the product ranked 12th in the top 20 pattern of paediatric cold medicine brands of Chinese patent medicine in public medical institutions in 2016   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, Yabao pharmaceutical comprehensively improved its management level and efficiency in terms of production, R & D and marketing, realizing a steady growth of revenue scale The operating revenue was 1.179 billion yuan, a year-on-year increase of 27.40%, and the net profit attributable to the common shareholders of the listed company was 107 million yuan, a year-on-year increase of 20.06% Figure 5: in the first half of the year, Yabao pharmaceutical made great efforts to increase product marketing and product echelon construction, and the blockbuster product dinggui'er navel sticker regained its growth momentum We should dig out the existing potential varieties and innovate the business mode, forming potential varieties such as Coix bud Jianpi gel, infantile diarrhea paste, Mosapride Citrate Tablets and gynostemma pentaphyllum glycosides dispersible tablets According to minenet data, in 2016, in the top 20 pattern of pediatric antidiarrheal brands of Chinese patent medicine in urban retail pharmacies in China, Yabao's Ding gui'er navel patch ranked first with a high market share of more than 94%   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, sunwater continued to maintain steady development, achieving operating revenue of 865 million yuan, an increase of 20.89% over the same period last year; net profit attributable to shareholders of listed companies was 147 million yuan, an increase of 38.58% over the same period last year Figure 6: Shanda Huate's performance Shanda Huate's pharmaceutical business is operated by its subsidiary, dyne pharmaceutical Dyne pharmaceutical focuses on children's treatment and health care, and its existing products mainly involve children's medicine, food and supplies Children's drugs mainly include vitamin AD drops (icoxin), compound calcium carbonate effervescent granules (gedixin), Glycyrrhiza zinc granules (iganxin), azithromycin granules, rifaximin dry suspension, dimercaptosuccinic acid capsules, etc Among them, ikosin is a well-known trademark in China, ranking first in the market share of similar products for many years In the first half of 2017, dyne pharmaceutical obtained the GMP certificate issued by the Australian drug administration Two specifications of icone products were listed in the Australian medical supplies registration form, and the production and quality management level of dyne pharmaceutical entered a new stage in line with international standards   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in the first half of 2017, Hansen pharmaceutical's overall business performance was good, with an operating revenue of 394 million yuan, an increase of 8.93% over the same period of last year; the net profit attributable to shareholders of listed companies was 53 million yuan, an increase of 5.27% over the same period of last year Figure 7: performance of Hansen pharmaceutical The main function of Simotang oral liquid, the leading product of Hansen pharmaceutical, is to smooth the flow of Qi, reduce adverse reactions, eliminate accumulation and relieve pain It can be used for infantile internal stagnation of milk and food, anorexia and anorexia, abdominal distention, abdominal pain, diarrhea or constipation, as well as middle-aged and old people's qi stagnation, accumulation of food, fullness of abdominal distention, abdominal pain, constipation, etc The sales volume in the first half of 2017 was 219 million yuan, an increase of 18.98% over the same period of the previous year, accounting for 55.51% of the company's operating revenue According to the data of minenet, from 2013 to 2016, in the top 20 pattern of pediatric anorexia drug brands in Chinese public medical institutions, the oral liquid level of Simotang ranked No